KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Working Capital Changes: 2018-2025

Historic Other Working Capital Changes for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $6.4 million.

  • Esperion Therapeutics' Other Working Capital Changes rose 138.82% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year increase of 435.87%. This contributed to the annual value of -$16.9 million for FY2024, which is 177.11% down from last year.
  • As of Q3 2025, Esperion Therapeutics' Other Working Capital Changes stood at $6.4 million, which was down 40.30% from $10.8 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Other Working Capital Changes registered a high of $10.8 million during Q2 2025, and its lowest value of -$16.6 million during Q3 2024.
  • For the 3-year period, Esperion Therapeutics' Other Working Capital Changes averaged around $2.5 million, with its median value being $4.9 million (2025).
  • In the last 5 years, Esperion Therapeutics' Other Working Capital Changes plummeted by 505.94% in 2024 and then soared by 3,526.35% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Other Working Capital Changes (Quarterly) stood at $2.4 million in 2021, then slumped by 122.38% to -$538,000 in 2022, then spiked by 1,155.58% to $5.7 million in 2023, then slumped by 215.51% to -$6.6 million in 2024, then surged by 138.82% to $6.4 million in 2025.
  • Its Other Working Capital Changes stands at $6.4 million for Q3 2025, versus $10.8 million for Q2 2025 and $4.9 million for Q1 2025.